doi: 10.1016/s0026-0495(98)90357-2
Pituitary tumors frequently preserve responsiveness to hypophysiotropic factors, including dopamine (DA) and somatostatin (SS), ubiquitous peptides that physiologically inhibit hormone secretion and cell proliferation at both the pituitary and the periphery levels, and thus are considered as molecules with therapeutical potential ( The inhibitory actions of DA in pituitary tumors are mediated by DA receptor subtype 2 (DRD2) [reviewed in Ref
Coco-Caprylate/Caprate, Olea Europaea (Olive) Fruit Oil, Isododecane, Hexylene Glycol, Salvia Hispanica Seed Oil, Isononyl Isononanoate, Linum Usitatissimum (Linseed) Seed Oil, Macadamia Ternifolia Seed Oil, Persea Gratissima (Avocado) Oil, Polysorbate 20, Prunus Amygdalus Dulcis (Sweet Almond) Oil, Argania Spinosa Kernel Oil, Fragrance (Parfum), Cholesterol, Ceramide NP, Linoleic Acid, Palmitic Acid, Linolenic Acid, Tocopherol, Ascorbyl Palmitate, S-Palmitoylglutathione, Stearic Acid, Myristic Acid, Limonene, Linalool, Hydroxycitronellal, Citronellol, Benzyl Alcohol
PMID 3239770
Absolute contraindications include: Active malignancy of any kind (GH and IGF-1 are growth-promoting signals) Active diabetic retinopathy (IGF-1 may worsen retinal vascularity) Pregnancy or breastfeeding Known hypersensitivity to any component of the formulation Pituitary tumours or untreated hypothalamic disease Relative contraindications requiring careful evaluation include pre-existing insulin resistance, type 2 diabetes, uncontrolled cardiovascular disease, and sleep apnoea (GH elevation can worsen upper airway tone in susceptible individuals)
Concurrently, substantial research efforts must elucidate the ferroptosis-modulating mechanisms of existing antineoplastic agents through integrated preclinical-clinical investigations, which is crucial for developing novel effective anti-myeloma therapeutics
